Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Completeness of follow-up is important, especially in clinical trials, since unequal follow-up in the treatment groups can bias the analysis of results. In survival studies, information on participants who do not complete the study is often omitted because their data can be included up to the time at which they were lost to follow-up. We propose a simple measure of completeness that is the ratio of the total observed person-time and the potential person-time of follow-up in a study. Our measure is easy to calculate, can be illustrated pictorially, and can be used to identify subgroups with especially poor follow-up.

Original publication

DOI

10.1016/s0140-6736(02)08272-7

Type

Journal article

Journal

Lancet (London, England)

Publication Date

04/2002

Volume

359

Pages

1309 - 1310

Keywords

Humans, Multiple Myeloma, Ovarian Neoplasms, Liver Cirrhosis, Biliary, Survival Analysis, Follow-Up Studies, Female, Clinical Trials as Topic